Articles related to ALZHEIMER'S DISEASE (AD)

Scientists have made a breakthrough when it comes to triggering lucid dreams. Building on their previous work, researchers at the University of Wisconsin–Madison and the Lucidity Institute in Hawaii wanted to investigate how acetylcholinesterase inhibitors might promote lucid dreaming. A common drug used to treat memory decline in Alzheimer’s disease – galantamine – is a fast-acting AChEI with only mild side effects, so researchers recruited 121 participants to see what effect the drug had on their ability to have and recall lucid dreams. The findings were surprising.

More than half of adult Americans (60%) have at least one chronic condition that eventually lead to disability, mortality, and reduced quality of life. And chronic conditions account for 90% of America’s $3.8 trillion in annual healthcare costs. The CDC says these are the eight most expensive.

We’ve all experienced a memory blip now and then, but these so-called “senior moments” could actually be signaling a bigger problem. Alzheimer’s disease (AD) is not a normal part of aging even though aging ups the risk for developing the condition. Here are 10 warning signs you can share with patients if they’re questioning what’s normal memory behavior and what’s not.  

MedPage Today presents this illuminating conversation with Daniel Gibbs, MD, PhD, a retired neurologist and author of the book, A Tattoo on my Brain: A Neurologist’s Personal Battle against Alzheimer’s Disease. In the question-and-answer session, Dr. Gibbs discusses his early diagnosis, his participation in clinical trials, and his experiences and unique perspectives as a neurologist with the disease.

In this MedPage Today interview with Jason Karlawish, MD, co-director of the Penn Memory Center at the University of Pennsylvania in Philadelphia and author of the new book, The Problem of Alzheimer’s: How Science, Culture, and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It, the  biomarker “revolution” is discussed, along with the discovery of the idea of mild cognitive impairment.

The numbers are staggering: fifty million people worldwide live with dementia, with the number expected to reach 152 million in 2050. Despite these seemingly overwhelming totals, the neurocognitive health of you and your patients is highly dependent on multiple factors. Here are five of them, all supported by evidence-based studies.